1.Brooks WA, Breiman RF, Goswami D, Hossain A, Alam K, Saha SK, Nahar K, Nasrin D, Ahmed N, El Arifeen S, Naheed A, Sack DA, Luby S. Invasive Pneumococcal Disease Burden and Implications for Vaccine Policy in Urban Bangladesh.Am J Trop Med Hyg. 77:795-801, 2007
2.Sack DA, Shimko J, Torres O, Bourgeois AL, Francia DS, Gustafsson B, Karnell A, Nyquist I, Svennerholm AM. Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico. Vaccine. 25:4392-400, 2007.
3.Alam K, Lastovica AJ, le Roux, E, b, Hossain MA, a, Islam MN, Sur GC, Sen SK a, G. Nair GB, Sack DA. Clinical characteristics and serotype distribution of Campylobacter jejuni and C. coli strains isolated from diarrhoeic patients in Dhaka, Bangladesh, and Cape Town, South Africa. Bangladesh J Microbiol. 23:121-124, 2006.
4.Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Al Tarique A, Seidlein LV, Park E, Killeen KP, Mekalanos JJ, Clemens JD, Sack DA; the PXV Study Group. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine. 25:231-8, 2007
5.Sack DA, Sack RB, Chaignat CL. Getting serious about cholera. N Engl J Med. 355:649-51, 2006.
6.Alam NH, Yunus M, Faruque AS, Gyr N, Sattar S, Parvin S, Ahmed JU, Salam MA, Sack DA. Symptomatic hyponatremia during treatment of dehydrating diarrheal disease with reduced osmolarity oral rehydration solution. JAMA. 296:567-73, 2006.
7.Raqib R, Sarker P, Bergman P, Ara G, Lindh M, Sack DA, Islam KM, Gudmundsson GH, Andersson J, Agerberth B. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci U S A. 103:9178-83 2006.
8.Faruque SM, Biswas K, Udden SM, Ahmad QS, Sack DA, Nair GB, Mekalanos JJ. Transmissibility of cholera: in vivo-formed biofilms and their relationship to infectivity and persistence in the environment. Proc Natl Acad Sci U S A. 103:6350-5, 2006
9.Zaman,K.; Yunus,M.; Arifeen,S.E.; Baqui,A.H.; Sack,D.A.; Hossain,S.; Rahim,Z.; Ali,M.; Banu,S.; Islam,M.A.; Begum,N.; Begum,V.; Breiman,R.F.; Black,R.E. Prevalence of sputum smear-positive tuberculosis in a rural area in Bangladesh Epidemiol Infect. 134:1052-9,2006.
10.Sack DA. Herd protection and herd amplification in cholera. J Health Popul Nutr. 24:1-5, 2006
11.Carpenter CM, Hall ER, Randall R, McKenzie R, Cassels F, Diaz N, Thomas N, Bedford P, Darsley M, Gewert C, Howard C, Sack RB, Sack DA, Chang HS, Gomes G, Bourgeois AL Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers. Vaccine. 24:3709-18, 2006
12.Qadri F, Ahmed T, Ahmed F, Begum YA, Sack DA, Svennerholm AM; The PTE Study Group. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: Dosing studies in different age groups. Vaccine. 6;24:1726-33, 2006.
13.McKenzie R, Bourgeois AL, Engstrom F, Hall E, Chang HS, Gomes JG, Kyle JL,Cassels F, Turner AK, Randall R, Darsley M, Lee C, Bedford P, Shimko J, Sack DA. Comparative Safety and Immunogenicity of Two Attenuated Enterotoxigenic Escherichia coli Vaccine Strains in Healthy Adults. Infect Immun. 74:994-1000, 2006.
14.Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M, Holmgren J, Clemens JD Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis.
Lancet. 366:44-9, 2005.
15.Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Alam MS, Zaman K, Seidlein LV, Park E, Killeen KP, Mekalanos JJ, Clemens JD, Sack DA; Peru-15 Study Group. Randomized, controlled study of the safety and immunogenicity of peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis. 192:573-9. 2005.
16.Faruque SM, Islam MJ, Ahmad QS, Faruque AS, Sack DA, Nair GB, Mekalanos JJ. Self-limiting nature of seasonal cholera epidemics: Role of host-mediated amplification of phage. Proc Natl Acad Sci U S A. 102:6119-24, 2005
17.Rabbani GH, Sack DA, Ahmed S, Peterson JW, Saha SK, Marni F, Thomas P. Antidiarrheal Effects of l-Histidine-Supplemented Rice-Based Oral Rehydration Solution in the Treatment of Male Adults with Severe Cholera in Bangladesh: A Double-Blind, Randomized Trial. J Infect Dis. 191:1507-14, 2005
18.Faruque SM, Naser IB, Islam MJ, Faruque AS, Ghosh AN, Nair GB, Sack DA, Mekalanos JJ. Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phages. Proc Natl Acad Sci U S A. 102:1702-7, 2005.
19.Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet. 363:223-33, 2004.
20.Sack DA When should cholera vaccine be used in cholera-endemic areas? J Health Popul Nutr. 21:299-303, 2003
21.Raqib R, Rahman J, Kamaluddin AK, Kamal SM, Banu FA, Ahmed S, Rahim Z, Bardhan PK, Andersson J, Sack DA. Rapid diagnosis of active tuberculosis by detecting antibodies from lymphocyte secretions. J Infect Dis. 188:364-70, 2003.
22.Qadri F, Ryan ET, Faruque AS, Ahmed F, Khan AI, Islam MM, Akramuzzaman SM, Sack DA, Calderwood SB. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect Immun. 71:4808-14, 2003.
23.Qadri F, Ahmed T, Ahmed F, Bradley Sack R, Sack DA, Svennerholm AM. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Vaccine. 21:2394-2403. 2003.
24.Steffen R, Sack DA, Riopel L, Jiang ZD, Sturchler M, Ericsson CD, Lowe B, Waiyaki P, White M, DuPont HL. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol. 98:1073-1078, 2003.
25.Sack RB, Siddique AK, Longini IM Jr, Nizam A, Yunus M, Islam MS, Morris JG Jr, Ali A, Huq A, Nair GB, Qadri F, Faruque SM, Sack DA, Colwell RR. A 4-year study of the epidemiology of Vibrio cholerae in four rural areas of Bangladesh. J Infect Dis. 187:96-101, 2003.
26.Nair GB, Faruque SM,Shuiyan NA, Kamruzzaman M, Siddique AK, Sack DA. New variants of Vibrio cholerae O1 biotype El Tor with attributes of the classical biotype from hospitalized patients with acute diarrhea in Bangladesh. J Clin Microbiol. 40:3296-3299,2002.
27.Turner AK, Terry TD, Sack DA, Londono-Arcila P, Darsley MJ. Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans. Infect Immun. 69:4969-79, 2001.
28.Chang HS, Sack DA.Development of a novel in vitro assay (ALS assay) for evaluation of vaccine-induced antibody secretion from circulating mucosal lymphocytes. Clin Diagn Lab Immunol. 8:482-8, 2001
29.K. Zaman, M Yunus, A. Rahman, HR Chowdhury, DA Sack. Efficacy of a Packaged Rice Oral Rehydration Solution Among Children With Cholera and Cholera-Like Illness. Acta Paediatrica 90:505-510, 2001.
30.Sack DA, Ahmed S, Razzaque A, Chakraborty J, Yunus M. Improved Infant Mortality Indicators for Integrated Primary Health Care Programs. J Health Popul Nutr 18:61-8, 2000.
31.Bernstein DI, Sack DA, Rothstein E, Reisinger K, Smith VE, O'Sullivan D, Spriggs DR, Ward RL. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet. 354:287-90, 1999.
